---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-001830"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:19:29.601306+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VolitionRx FY2025 revenue up 40% to $1.7M; net loss down 14%

## Summary
- Full-year revenue $1.7M (+40% YoY); Q4 revenue growth 133% vs prior year.
- Operating expenses down $4.8M (17%); net cash used in ops $19.7M (-24%).
- Received first order for Nu.Q Cancer assays for lung cancer clinical certification.
- Nu.Q NETs assay included in French government-backed sepsis study (~$7.3M).
- Subsequent to year end: raised $5.4M ATM equity, $1.9M convertible note, $1.0M non-dilutive.

## SEC filing metadata
- accession: 0001477932-26-001830
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793226001830/0001477932-26-001830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793226001830/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-001830
- JSON: https://secwatch.observer/filing/0001477932-26-001830.json
- Plain text: https://secwatch.observer/filing/0001477932-26-001830.txt

## Key facts
- Earnings Releases
  VOLITIONRX LTD reported full fiscal year 2025 results: revenue $1.7 million.
  - Period: full fiscal year 2025
  - Revenue: $1.7 million
  - Result: reported results
  source text: Full-year revenue for 2025 was $1.7 million, representing growth of 40% over the previous year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/93314/000147793226001830/0001477932-26-001830-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.